NEW YORK (360Dx) – Life is not the same for young startup diagnostic companies in this "post-Theranos world," but Philadelphia-based Group K Diagnostics and its CEO Brianna Wronko are undaunted, according to early-stage venture accelerator Dreamit.
NEW YORK (360Dx) – Life is not the same for young startup diagnostic companies in this "post-Theranos world," but Philadelphia-based Group K Diagnostics and its CEO Brianna Wronko are undaunted, according to early-stage venture accelerator Dreamit.
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.